THE ANABOLICPROTOCOL
MedicationsMedium risk

Finasteride (Propecia)

Also known as: Propecia, Finasterid, Proscar, Fin, Finasteride

Blocks the conversion of testosterone to DHT — effective against androgenetic hair loss, and useless against the DHT derivatives, because those are already past the step it blocks.

Substance family

Hair loss agents

Which one works depends entirely on the cause. 5-alpha-reductase inhibitors block a conversion; receptor blockers block the receptor; minoxidil acts on the growth cycle regardless of androgens.

Effects on

Which outcomes this substance acts on — descriptive, not a recommendation.

Strain profile

Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.

Liver
low
Kidneys
minimal
Blood lipids
minimal
Hematocrit
minimal
Blood pressure
minimal
Hormonal axis
low

This substance works against

Dosing & protocols by goal

Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.

Androgenetic alopecia (approved indication)

Medical

Dose

1 mg / day

Frequency

1× daily

Cycle length

Ongoing — the effect ends when the drug does

Suppresses DHT by roughly 65–70%. Visible results take 3–6 months; anyone judging earlier is judging too early.

Prostate enlargement (approved indication)

Medical

Dose

5 mg / day

Frequency

1× daily

Cycle length

Ongoing, medically supervised

The higher dose for a different indication. It does not produce better hair results — DHT suppression is already near maximal at 1 mg.

Lower-dose approach

Advanced

Dose

0.5 mg / day or 1 mg every other day

Frequency

Daily or alternating

Cycle length

Ongoing

Used to reduce side effects. DHT suppression falls only modestly, since the dose-response curve is flat in this range.

Supraphysiological doses carry significant health risks and are not legal without a medical indication. This information serves education and harm reduction, not as a usage recommendation. Accompanying blood work and — where relevant — a post-cycle plan (PCT) are essential. See the disclaimer.

Side effect & countermeasure

Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.

Problem

No effect against DHT-derived compounds

Countermeasure

This is the point most often misunderstood. Finasteride blocks the conversion of testosterone to DHT. Drostanolone, stanozolol, oxandrolone and methenolone are already DHT derivatives — there is no conversion left to block. Against hair loss driven by those, minoxidil works (DHT-independent) or a topical receptor blocker such as RU58841.

Problem

Sexual side effects: reduced libido, erectile dysfunction

Countermeasure

Reported in a few percent in trials, higher in observational data. If they appear, stopping usually resolves them within weeks. A lower dose is worth trying first, since DHT suppression barely drops.

Problem

Persistent symptoms after stopping (post-finasteride syndrome)

Countermeasure

Contested in the literature but consistently reported: sexual, cognitive and mood symptoms persisting after discontinuation. The mechanism is unclear and the incidence disputed. What is not disputed is that it is described often enough to belong in the decision — particularly for anyone with a history of depression.

Problem

Mood changes and depressive symptoms

Countermeasure

5-alpha-reductase also produces neurosteroids such as allopregnanolone, which act on the GABA system. This is the plausible mechanism behind the mood effects. Pre-existing depression is a reason to discuss alternatives with a doctor.

Problem

Distorted PSA readings

Countermeasure

Finasteride roughly halves PSA. A value that looks normal may not be — tell any doctor measuring PSA that you take it, otherwise prostate screening becomes unreliable.

Problem

Estradiol rising

Countermeasure

Testosterone that is not converted to DHT remains available for aromatisation. Estradiol can rise modestly. Relevant for anyone already managing it.

Overview

Finasteride blocks the enzyme that converts testosterone into dihydrotestosterone. DHT is the androgen responsible for androgenetic hair loss — it binds to receptors in genetically susceptible follicles and progressively miniaturises them.

Reducing DHT slows or halts that process. The approved dose of one milligram suppresses DHT by roughly two thirds, and in trials that translates into stabilised hair in the majority of users and regrowth in a substantial minority.

In the context of this site, one property matters more than the general hair-loss discussion: what finasteride can and cannot do depends entirely on which compound is causing the problem.

Mechanism of Action

Testosterone is converted to DHT by 5-alpha-reductase. DHT binds the androgen receptor far more strongly than testosterone does — several times over — which is why it dominates in tissues sensitive to it: hair follicles, prostate, skin.

Finasteride inhibits the type 2 isoform of that enzyme, which is the one dominant in hair follicles and prostate. Dutasteride blocks both isoforms and suppresses DHT further.

Here is the part that matters for anyone running anabolic compounds. Finasteride works at the conversion step. It reduces how much DHT is made from testosterone.

Drostanolone, stanozolol, oxandrolone and methenolone are not converted into DHT — they are DHT derivatives. They arrive already past the step finasteride blocks. Taking finasteride alongside them changes nothing about the androgenic pressure on the follicle, which is exactly why the hair loss under those compounds continues regardless.

What does work in that situation acts elsewhere: minoxidil, which stimulates follicles through a mechanism unrelated to DHT, or a topical androgen receptor blocker such as RU58841, which occupies the receptor rather than reducing the hormone reaching it.

Typical Context

One milligram daily, indefinitely — the effect lasts as long as the drug is taken, and hair lost after stopping is lost. Results become visible after three to six months, which is worth knowing before concluding it does not work.

Lower doses are used to reduce side effects, and the pharmacology supports it: DHT suppression at half a milligram is only slightly lower than at one, because the dose-response curve flattens early. Anyone experiencing side effects has that option before abandoning the drug entirely.

The side-effect discussion around finasteride is unusually polarised. Trial data shows sexual side effects in a low single-digit percentage, resolving on discontinuation. Observational reports describe higher rates and, in some cases, symptoms persisting after stopping — post-finasteride syndrome. The mechanism is unclear, the incidence is disputed, and the topic is genuinely unresolved. What can be said honestly: it is reported often enough to belong in an informed decision, and a history of depression is a reason to discuss it with a doctor rather than start on a whim.

Side Effects & Risks

  • Reduced libido, erectile dysfunction, reduced ejaculate volume
  • Mood changes, depressive symptoms
  • Persistent symptoms after discontinuation in some reports (post-finasteride syndrome)
  • Gynecomastia, rarely
  • Modest rise in estradiol
  • PSA readings roughly halved, distorting prostate screening
  • No effect on hair loss driven by DHT-derived compounds

Blood Work & Monitoring

  • PSA — halved by finasteride; the treating doctor needs to know for correct interpretation
  • Estradiol (sensitive) — can rise modestly
  • Total/free testosterone — usually rises slightly
  • DHT — measurable if the effect needs confirming, though rarely necessary

Harm-Reduction Notes

  • Useless against drostanolone, stanozolol, oxandrolone and methenolone — those are already DHT derivatives
  • For DHT-derivative-driven loss, minoxidil or a topical receptor blocker are the mechanisms that apply
  • Allow 3–6 months before judging the effect
  • If side effects appear, try a lower dose before stopping entirely — suppression barely drops
  • Tell any doctor measuring PSA that you take it
  • A history of depression belongs in the decision, given the reported mood effects
  • The effect ends when the drug does; hair kept is kept only while taking it

Legal status by region

Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.

RegionRegulatory status
United StatesPrescription-only medicineApproved for androgenetic alopecia (1 mg) and prostate enlargement (5 mg).
EU / UKPrescription-only medicine
Canada / AustraliaPrescription-only medicine
Parts of Asia, Latin America & Middle EastPharmacy availability variesDispensed without prescription in several countries.
Competitive sportNot prohibitedWas on the WADA list as a masking agent until 2009; removed since.
All content on this page is for information and harm-reduction purposes only. It is not medical advice, not a recommendation to purchase or use, and does not replace consulting a doctor. Legal status and enforcement vary by country and change; verifying the current rules in your own jurisdiction is your responsibility. For adults 18+ only. See the full disclaimer.